Financial giants have made a conspicuous bearish move on Capricor Therapeutics. Our analysis of options history for Capricor Therapeutics CAPR revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $180,000, and 6 were calls, valued at $340,710.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $30.0 for Capricor Therapeutics over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capricor Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capricor Therapeutics's whale activity within a strike price range from $10.0 to $30.0 in the last 30 days.
Capricor Therapeutics Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | PUT | SWEEP | BEARISH | 04/17/25 | $0.75 | $0.5 | $0.75 | $12.50 | $150.0K | 456 | 2.0K |
| CAPR | CALL | TRADE | BEARISH | 05/16/25 | $0.9 | $0.75 | $0.75 | $15.00 | $89.2K | 4.1K | 1.5K |
| CAPR | CALL | TRADE | NEUTRAL | 04/17/25 | $0.5 | $0.3 | $0.4 | $15.00 | $80.0K | 3.4K | 2.0K |
| CAPR | CALL | TRADE | BEARISH | 05/16/25 | $1.0 | $0.85 | $0.75 | $15.00 | $51.7K | 4.1K | 1.0K |
| CAPR | CALL | SWEEP | BEARISH | 09/19/25 | $5.0 | $4.5 | $4.5 | $15.00 | $44.1K | 1.5K | 101 |
About Capricor Therapeutics
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Following our analysis of the options activities associated with Capricor Therapeutics, we pivot to a closer look at the company's own performance.
Capricor Therapeutics's Current Market Status
- With a trading volume of 1,069,496, the price of CAPR is down by -9.18%, reaching $11.97.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 46 days from now.
Expert Opinions on Capricor Therapeutics
4 market experts have recently issued ratings for this stock, with a consensus target price of $65.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $77. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $77. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $77. * In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $30.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Capricor Therapeutics options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
